Metabolite Profiling and Pharmacokinetic Evaluation of Hydrocortisone in a Perfused Three-Dimensional Human Liver Bioreactor

被引:68
作者
Sarkar, Ujjal [1 ]
Rivera-Burgos, Dinelia [1 ]
Large, Emma M. [4 ]
Hughes, David J. [4 ]
Ravindra, Kodihalli C. [1 ]
Dyer, Rachel L. [1 ]
Ebrahimkhani, Mohammad R. [1 ]
Wishnok, John S. [1 ]
Griffith, Linda G. [1 ,3 ]
Tannenbaum, Steven R. [1 ,2 ]
机构
[1] MIT, Dept Biol Engn, MIT Room 56-731,77 Massachusetts Ave, Cambridge, MA 02139 USA
[2] MIT, Dept Chem, Cambridge, MA 02139 USA
[3] MIT, Dept Mech Engn, Cambridge, MA 02139 USA
[4] Univ Oxford, CN Bio Innovat, Begbroke Sci Pk, Begbroke, Oxon, England
基金
美国国家卫生研究院;
关键词
ADULT-RAT HEPATOCYTES; KUPFFER CELLS; SPECIES-DIFFERENCES; HEPATIC-CLEARANCE; COCULTURE SYSTEM; DRUG-METABOLISM; CORTISOL; MECHANISMS; INDUCTION; TOXICITY;
D O I
10.1124/dmd.115.063495
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Endotoxin lipopolysaccharide (LPS) is known to cause liver injury primarily involving inflammatory cells such as Kupffer cells, but few in vitro culture models are applicable for investigation of inflammatory effects on drug metabolism. We have developed a threedimensional human microphysiological hepatocyte-Kupffer cell coculture system and evaluated the anti-inflammatory effect of glucocorticoids on liver cultures. LPS was introduced to the cultures to elicit an inflammatory response and was assessed by the release of proinflammatory cytokines, interleukin 6 and tumor necrosis factor alpha. A sensitive and specific reversed-phase-ultra high-performance liquid chromatography-quadrupole time of flight-mass spectrometry method was used to evaluate hydrocortisone disappearance and metabolism at near physiologic levels. For this, the systems were dosed with 100 nM hydrocortisone and circulated for 2 days; hydrocortisone was depleted to approximately 30 nM, with first-order kinetics. Phase I metabolites, including tetrahydrocortisone and dihydrocortisol, accounted for 8-10% of the loss, and 45-52% consisted of phase II metabolites, including glucuronides of tetrahydrocortisol and tetrahydrocortisone. Pharmacokinetic parameters, i.e., half-life, rate of elimination, clearance, and area under the curve, were 23.03 hours, 0.03 hour(-1), 6.6 x 10(25) l.hour(-1), and 1.03 (mg/l)(star)h, respectively. The ability of the bioreactor to predict the in vivo clearance of hydrocortisone was characterized, and the obtained intrinsic clearance values correlated with human data. This system offers a physiologically relevant tool for investigating hepatic function in an inflamed liver.
引用
收藏
页码:1091 / 1099
页数:9
相关论文
共 57 条
  • [1] Mechanisms of Immune-Mediated Liver Injury
    Adams, David H.
    Ju, Cynthia
    Ramaiah, Shashi K.
    Uetrecht, Jack
    Jaeschke, Hartmut
    [J]. TOXICOLOGICAL SCIENCES, 2010, 115 (02) : 307 - 321
  • [2] HYDROCORTISONE MODULATES THE PRODUCTION OF EXTRACELLULAR MATERIAL AND ALBUMIN IN LONG-TERM COCULTURES OF ADULT-RAT HEPATOCYTES WITH OTHER LIVER EPITHELIAL-CELLS
    BAFFET, G
    CLEMENT, B
    GLAISE, D
    GUILLOUZO, A
    GUGUENGUILLOUZO, C
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1982, 109 (02) : 507 - 512
  • [3] Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man
    Bayliss, MK
    Bell, JA
    Jenner, WN
    Park, GR
    Wilson, K
    [J]. XENOBIOTICA, 1999, 29 (03) : 253 - 268
  • [4] Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac
    Chan, Tom S.
    Yu, Hongbin
    Moore, Amanda
    Khetani, Salman R.
    Tweedie, Donald
    [J]. DRUG METABOLISM AND DISPOSITION, 2013, 41 (12) : 2024 - 2032
  • [5] Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development
    Chiba, Masato
    Ishii, Yasuyuki
    Sugiyama, Yuichi
    [J]. AAPS JOURNAL, 2009, 11 (02): : 262 - 276
  • [6] Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity
    Cosgrove, Benjamin D.
    King, Bracken M.
    Hasan, Maya A.
    Alexopoulos, Leonidas G.
    Farazi, Paraskevi A.
    Hendriks, Bart S.
    Griffith, Linda G.
    Sorger, Peter K.
    Tidor, Bruce
    Xu, Jinghai J.
    Lauffenburger, Douglas A.
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2009, 237 (03) : 317 - 330
  • [7] Organotypic systems in drug metabolism and toxicity: challenges and opportunities
    Dash, Ajit
    Blackman, Brett R.
    Wamhoff, Brian R.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (08) : 999 - 1014
  • [8] Liver tissue engineering in the evaluation of drug safety
    Dash, Ajit
    Inman, Walker
    Hoffmaster, Keith
    Sevidal, Samantha
    Kelly, Joan
    Obach, R. Scott
    Griffith, Linda G.
    Tannenbaum, Steven R.
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (10) : 1159 - 1174
  • [9] PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS
    DAVIES, B
    MORRIS, T
    [J]. PHARMACEUTICAL RESEARCH, 1993, 10 (07) : 1093 - 1095
  • [10] Gene Expression Profiles in Livers from Diclofenac-Treated Rats Reveal Intestinal Bacteria-Dependent and -Independent Pathways Associated with Liver Injury
    Deng, Xiaomin
    Liguori, Michael J.
    Sparkenbaugh, Erica M.
    Waring, Jeffrey F.
    Blomme, Eric A. G.
    Ganey, Patricia E.
    Roth, Robert A.
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (03) : 634 - 644